

Commercial/Healthcare Exchange PA Criteria

Effective: January 1, 2020

Prior Authorization: Oseni (alogliptin benzoate/pioglitazone hydrochloride) oral tablets

Products Affected: Oseni tablets, alogliptin/pioglitazone tablets

<u>Medication Description</u>: Oseni is a fixed-dose combination product of alogliptin benzoate and pioglitazone hydrochloride combines 2 antihyperglycemic agents which act differently to achieve glycemic control in patients with type 2 diabetes. Alogliptin benzoate is a dipeptidyl peptidase-4 (DPP-4) inhibitor that reduces fasting and postprandial glucose concentrations in a glucose-dependent manner by slowing the inactivation of incretin hormones (eg, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by binding to and inhibiting the DPP-4 enzyme. Pioglitazone hydrochloride, a member of the thiazolidinedione class, works as an insulin-sensitizing agent to improve peripheral glucose utilization.

<u>Covered Uses</u>: Is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and pioglitazone is appropriate.

Exclusion Criteria:

- 1. Hypersensitivity to alogliptin, pioglitazone, or to any component of the product
- 2. NYHA Class III or IV heart failure

Required Medical Information:

- 1. Diagnosis
- 2. Chart Notes

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria: Approve if the following criteria is met:

- 1. Patient has the diagnosis of type 2 diabetes mellitus; AND
- 2. Patient has experienced an inadequate treatment response, intolerance, or contraindication to Januvia AND Tradjenta.

References:

Product Information: OSENI oral tablets, alogliptin pioglitazone oral tablets. Takeda Pharmaceuticals America, Inc. (per manufacturer), Deerfield, IL, 2013.

Last Reviewed October 21, 2019





Policy Revision history

Rev#	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/21/2019